Hutchin Hill Capital’s Myriad Genetics MYGN Stock Holding History

Hutchin Hill Capital’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-11,900	Closed	-$514K	–	728
2015 Q4	$514K	Buy	+11,900	New	+$503K	0.01%	518
2015 Q1	–	Sell	-66,400	Closed	-$2.26M	–	754
2014 Q4	$2.26M	Sell	66,400 -63,700	-49%	-$2.26M	0.08%	223
2014 Q3	$5.02M	Buy	130,100 +2,600	+2%	+$97K	0.19%	110
2014 Q2	$4.96M	Buy	127,500 +102,300	+406%	+$3.81M	0.23%	74
2014 Q1	$862K	Buy	+25,200	New	+$781K	0.04%	365
2013 Q4	–	Sell	-216,500	Closed	-$5.09M	–	608
2013 Q3	$5.09M	Buy	+216,500	New	+$6.15M	0.46%	49

Other funds holding MYGN

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Hutchin Hill Capital's MYGN Position: Q1 2016 in Review

Hutchin Hill Capital sold out of Myriad Genetics (MYGN) in Q1 2016, closing a stake of 11,900 shares — an estimated $514K sold.

Hutchin Hill Capital first reported a position in MYGN in Q3 2013 and held it in 6 quarters. The position peaked at $5.09M in Q3 2013. 233 funds tracked by Wall St. Rank hold MYGN as of Q1 2016.

Hutchin Hill Capital reported no remaining Myriad Genetics position as of Q1 2016 after selling out during the quarter.
Hutchin Hill Capital sold 11,900 Myriad Genetics shares in Q1 2016, an estimated $514K.
Hutchin Hill Capital first reported a position in Myriad Genetics in Q3 2013 and held it in 6 quarters.
Hutchin Hill Capital's Myriad Genetics position peaked at $5.09M in Q3 2013.
233 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2016.

Based on Hutchin Hill Capital's 13F filing for Q1 2016, filed 16 May 2016.